ScreenerHero

GOVX GeoVax Labs, Inc.

NAS · US · Healthcare · Biotechnology · geovax.com
0.2866USD-0.97%Mkt Cap: 2.90M $P/E: —

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap2.90M USD
Enterprise Value-694.25K USD
Revenue (TTM)0 USD
Gross Profit-15.05M USD
Net Income (TTM)-21.46M USD
Revenue/Share0.00 USD
Last Price0.2866 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.34
PEG—
EV/EBITDA0.03
EV/Revenue—
P/SInfinity
P/B1.21
EPS (TTM)-7.88
EPS (Forward)-0.86
52W Range
0.27650% of range16.80
52W High16.80 USD
52W Low0.2765 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-862.34%
ROE-561.15%
ROA-338.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.47M USD
CapEx (TTM)27.61K USD
FCF Margin—
FCF Yield-373.68%
Net Debt-2.82M USD
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity0.22
Current Ratio1.54
Quick Ratio1.16
Book Value/Sh0.24 USD
Cash/Share0.43 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 25, 2020
Splits
Last Split1:25
Split DateJan 12, 2026
Analyst Consensus
Rating—
Target (Mean)10.00 USD
Upside (mean)+3389.2%
Target Range10.00 USD – 10.00 USD
# Analysts2
Ownership
Shares Out.10.10M
Float6.92M
Insiders0.03%
Institutions9.77%
Short Interest
Short Ratio0.4d
Short % Float4.94%
Short % Out.4.94%
Shares Short498.70K
Short (prev mo.)182.36K
Technical
SMA 500.5593 (-48.8%)
SMA 2001.667 (-82.8%)
Beta3.69
S&P 52W Chg16.45%
Avg Vol (30d)1.17M
Avg Vol (10d)1.35M
Technical Indicators
RSI (14)22.4
MACD-0.0865
MACD Signal-0.0948
MACD Hist.+0.0082
BB Upper0.4790 USD
BB Middle0.3637 USD
BB Lower0.2483 USD
BB Width63.44%
ATR (14)0.0505 USD
Vol Ratio (20d)0.37x